After the final jobs report for 2019 showed wage growth missed expectations, the Dow closed below 29,000 after reaching the milestone for the first time in intraday trading.
But Grover Norquist, conservative activist and president of the advocacy group Americans for Tax Reform, said the jobs report was “good on all counts”
“I particularly like the U6, which is the unemployment number that includes discouraged workers,” he told Cheddar. Discouraged workers are those individuals who stop looking for jobs and no longer count toward general unemployment numbers.
“Unemployment is at a historic 50-year low, but discouraged workers is also at an all-time low,” he said. The discouraged and underemployed workers rate fell to 6.7 percent. He noted that the number is the lowest since the government began being measured in 1994.
In today’s report, the Labor Department said nonfarm payrolls increased by only 145,000 versus the 160,000 that had been expected as the unemployment rate held steady at 3.5 percent.
Today’s report also marked a slow rise in average hourly earnings, which rose by 2.9 percent, below the 3.1 percent projection.
Of those employed, women held more U.S. jobs than men for the first time in a decade. The last time women overtook men in payrolls was between January 2009 and April 2010, according to the Wall Street Journal.
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d